Literature DB >> 8190185

Renal lesions of the FGS strain of mice: a spontaneous animal model of progressive glomerulosclerosis.

F Yoshida1, S Matsuo, H Fujishima, H K Kim, T Tomita.   

Abstract

The strain of FGS/Nga mouse is reported to develop proteinuria and progressive glomerulosclerosis. We studied the renal pathology of that strain periodically for 1 year. Focal and segmental glomerulosclerosis was observed 3 months after birth and the lesion progressed to the glomerular obsolescence in a year. Electron microscopic study revealed electron dense deposits (DD) in the mesangium and the splitting of glomerular basement membrane. Studies using immunofluorescence and immunoelectron microscopy revealed that these DD were contained IgA, IgM, C3 and the retroviral envelope antigen (gp70). Clinically, proteinuria began at the age of 3 months and the renal function was decreased on time course. No other organs were involved. We studied the renal lesions of FGS mice by the histological and immunohistochemical methods and concluded that this mouse strain provides the tool for studying the mechanisms of the progression of glomerulosclerosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8190185     DOI: 10.1159/000187830

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

1.  Quantitative trait loci for proteinuria in the focal glomerulosclerosis mouse model.

Authors:  Eun-Hee Kim; Chul-Ho Lee; Byung-Hwa Hyun; Jun-Gyo Suh; Yang-Seok Oh; Takao Namikawa; Akira Ishikawa
Journal:  Mamm Genome       Date:  2005-04       Impact factor: 2.957

Review 2.  Monoclonal antibodies for podocytopathies: rationale and clinical responses.

Authors:  Maddalena Marasà; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2009-06       Impact factor: 28.314

Review 3.  Pathophysiology and treatment of focal segmental glomerulosclerosis: the role of animal models.

Authors:  Sylvana M L de Mik; Martin J Hoogduijn; Ron W de Bruin; Frank J M F Dor
Journal:  BMC Nephrol       Date:  2013-04-01       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.